missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Peptide Histidine-Methionine Monoclonal Antibody (03)

Mouse Monoclonal Antibody
Brand: Invitrogen™ ABS0200302
This item is not returnable.
View return policy
Description
ABS 020-03-02 detects PHM in human samples. ABS 020-03-02 has been successfully used in ELISA procedures. PHM cross-reacts with PACAP (approximately 12%; incomplete, non-parallel inhibition). NOTE: Concentration is lot-dependent and can vary from 0.85-1.15 mg/mL.
Human peptide histidine-methionine (PHM) is a 27-amino-acid peptide belonging to the glucagon-secretin family of peptide hormones. PHM is produced from the same prohormone as VIP, with which it shows considerable sequence homology. The VIP/PHM prohormone is produced by neurons in the central and peripheral nervous systems, often together with acetylcholine. In some situations the effect of the peptides is to reinforce and prolong the effects of neurotransmitter release. Like VIP, PHM is a vasodilator and stimulator of intestinal fluid secretion. High plasma levels of PHM are diagnostic of the corresponding peptide-producing tumor (VIPoma), associated with the watery diarrhea-hypokalemia-achlorhydria syndrome.
Specifications
| Peptide Histidine-Methionine | |
| Monoclonal | |
| 1 mg/mL | |
| PBS with 15mM sodium azide; pH 7.4 | |
| P01282 | |
| VIP | |
| Synthetic human peptide histidine-methionine. | |
| 400 μL | |
| Primary | |
| Human | |
| Antibody | |
| IgG2a κ |
| ELISA, Immunohistochemistry | |
| 03 | |
| Unconjugated | |
| VIP | |
| Intestinal peptide PHM-27; Intestinal peptide PHV-42; MGC13587; Peptide histidine methioninamide 27; Peptide histidine valine 42; PHM27; prepro-VIP; vasoactive intestinal peptide; Vasoactive intestinal polypeptide; VIP; VIP peptides | |
| Mouse | |
| Protein A/G | |
| RUO | |
| 7432 | |
| 4°C, store in dark | |
| Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction